The Ultimate Dividend King: 62 Years and Counting

Johnson & Johnson (NYSE: JNJ) stands as one of the most reliable dividend stocks in history. With 62 consecutive years of dividend increases, JNJ has raised its payout through every recession, market crash, and economic crisis since 1964.

That includes the 1970s stagflation, the 2000 dot-com crash, the 2008 financial crisis, the 2020 COVID pandemic, and the 2022 bear market. Through wars, recessions, and panics, JNJ has never missed a dividend increase.

This isn't just consistency—it's reliability engineered into the business model. JNJ's diversification across pharmaceuticals (60%) and medical devices (30%) creates recession-proof cash flow. People need cancer drugs and hip replacements regardless of GDP growth.

But the story changed in 2023 with the Kenvue spinoff. JNJ split off its consumer health division (Tylenol, Band-Aid, Neutrogena) to focus on higher-margin pharma and MedTech. This reduced revenue but increased profit margins and growth potential.

Today, JNJ offers a 3.0% yield with 5-6% annual growth, a 48% payout ratio, and a pharmaceutical pipeline worth tens of billions. For dividend investors seeking reliability over excitement, JNJ remains the gold standard.

62-Year Dividend History: The Chart That Never Dips

Johnson & Johnson has increased its dividend every single year since 1964. That's 62 consecutive years without a single freeze, cut, or pause. Only 54 companies globally can make this claim—the exclusive Dividend Kings club.

Notice the consistency: increases of 5-7% annually, with occasional years above 7% when earnings accelerate. JNJ targets dividend growth slightly above earnings growth to maintain the payout ratio.

The 2023 Kenvue spinoff didn't interrupt the streak. JNJ maintained the dividend on the smaller post-spinoff entity, and shareholders received Kenvue stock as a special dividend. Total shareholder income actually increased.

Looking back 20 years, the 2006 dividend was $1.62. The 2026 dividend is $4.84. That's a 199% total increase, or 5.6% compounded annually for two decades. A $10,000 investment in 2006 now generates nearly 3x the income.

Current Dividend Metrics (2026)

These metrics tell a simple story: safety and reliability. A 3.0% yield places JNJ above the S&P 500 average (1.6%) but below high-risk yield traps. The 5.8% growth rate means your income doubles every 12 years through dividend raises alone.

The 48% payout ratio is the crown jewel. JNJ could maintain this dividend even if earnings fell 50% overnight. That's why JNJ never cuts during recessions—there's always a massive cushion of retained earnings to protect the payout.

The Kenvue Spinoff: What Happened and Why It Matters

In August 2023, Johnson & Johnson completed one of the largest corporate spinoffs in history. The consumer health division—brands like Tylenol, Listerine, Band-Aid, Neutrogena, and Aveeno—became an independent company called Kenvue (NYSE: KVUE).

JNJ shareholders received 0.78 shares of Kenvue for every JNJ share owned. If you owned 100 shares of JNJ pre-spinoff, you now own 100 shares of JNJ plus 78 shares of Kenvue.

Why did JNJ do this? Three strategic reasons:

• Higher margins: Consumer products had 18-20% margins vs. 35-40% for pharma. Shedding low-margin revenue increases overall profitability.
• Faster growth: Pharma grows 6-8% annually with blockbuster drugs. Consumer grew 3-4% in mature markets. JNJ can now focus capital on high-return R&D.
• Litigation isolation: Most talc lawsuits targeted consumer products. The spinoff legally separates these liabilities from the core JNJ entity.

Impact on the dividend: JNJ maintained its $4.24 annual dividend post-spinoff on the smaller revenue base. This actually increased the yield from 2.7% to 3.0%. Plus, Kenvue pays its own 3.4% dividend, so total income to shareholders increased.

Think of it like a stock split for income. You went from owning one company paying $4.24 to owning two companies paying a combined $5.50+ in dividends. The Dividend King streak continues uninterrupted.

Business Segment Analysis: Pharma + MedTech

Post-Kenvue, Johnson & Johnson is a pure-play healthcare company focused on two high-margin, high-growth segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices).

The magic is in the mix. Pharmaceuticals provide high margins (35-40%) and recurring revenue from chronic conditions requiring lifelong treatment. MedTech offers recession resistance—hip replacements and cataract surgeries aren't optional for aging populations.

Together, these segments create a cash flow machine. JNJ generates $18-20B in annual free cash flow, of which only $13-14B goes to dividends. The remaining $5-6B funds R&D, acquisitions, and buybacks.

This is why the dividend never stops growing. Even in a recession, healthcare spending remains stable. Cancer patients don't delay chemotherapy. Diabetics don't stop buying insulin. JNJ's revenue stream is as reliable as they come.

Pharmaceutical Pipeline: The Growth Engine

JNJ's pharmaceutical division drives dividend growth through blockbuster drugs protected by patents. The current pipeline includes cancer immunotherapies, next-generation biologics, and CAR-T cell therapies worth billions in future revenue.

Darzalex is the crown jewel—an $8B+ blockbuster growing 15% annually. It's becoming the standard of care for multiple myeloma, with new indications expanding the addressable market. Patent protection runs through 2031.

Tremfya represents the next generation. As Stelara faces biosimilar competition after 2025, Tremfya is positioned as the superior replacement with better efficacy and dosing. The 28% growth rate shows physician adoption accelerating.

Carvykti is the moonshot. This CAR-T therapy rewrites immune cells to attack cancer. At $475,000 per treatment, it only needs 2,000 patients to generate $950M in revenue. Early approval for earlier-stage cancer could create a $5B+ blockbuster by 2030.

The pipeline extends beyond these five. JNJ has 50+ drugs in Phase 2 or Phase 3 trials across oncology, immunology, neuroscience, and cardiovascular disease. The R&D budget of $15B annually ensures a steady stream of future blockbusters.

Litigation Risks: Talc, Opioids, and Ring-Fencing

No analysis of JNJ is complete without addressing litigation. The company faces billions in potential liabilities from talc-based baby powder lawsuits and opioid-related claims. But the risk to the dividend is lower than headlines suggest.

The key question: Can litigation bankrupt JNJ or force a dividend cut? The answer is almost certainly no. Here's why:

• Ring-fencing via bankruptcy: The Texas Two-Step strategy isolates talc liabilities in a separate entity. Courts have upheld this approach, capping JNJ's exposure at $8-10B paid over 25+ years (~$400M annually).
• Cash reserves: JNJ holds $15B in cash and generates $18-20B in annual free cash flow. Even paying $2B/year in litigation costs, there's $16B+ left for dividends, R&D, and buybacks.
• Insurance coverage: JNJ carries extensive liability insurance that covers portions of settlement costs. The company's out-of-pocket costs are lower than headline numbers suggest.
• Historical precedent: JNJ has faced major lawsuits for decades (Risperdal, DePuy hips, Xarelto bleeding) and never missed a dividend increase. Management prioritizes shareholder returns above all else.

Bottom line: Litigation is a risk to monitor, not a reason to avoid the stock. JNJ's balance sheet can absorb tens of billions in settlements without impairing the dividend. The 62-year streak isn't ending because of talc powder.

Dividend Safety Score: 95/100 (Exceptional)

We rate JNJ's dividend safety at 95 out of 100—among the highest scores in the entire stock market. Only a handful of companies (Microsoft, Apple, Berkshire Hathaway) earn similar ratings.

The only factor preventing a perfect 100/100 score is litigation overhang. While we believe the risks are manageable, a catastrophic legal outcome could theoretically impact capital allocation. This represents perhaps 5% downside risk to the safety score.

For perspective, JNJ's safety score of 95/100 compares to:

• Pfizer: 65/100 (high payout ratio, COVID revenue cliff)
• AbbVie: 82/100 (Humira biosimilar pressure)
• Abbott: 90/100 (excellent diversification)
• Medtronic: 85/100 (medical device cyclicality)

If you want to sleep well at night knowing your dividend is safe through any economic storm, JNJ is as good as it gets. This is the stock you buy and never sell.

vs. Healthcare Dividend Peers

How does JNJ stack up against other healthcare dividend stocks? Let's compare the top 5 options for dividend investors in the healthcare sector.

Johnson & Johnson (JNJ) offers the best balance of yield, safety, and growth. The 3.0% yield beats high-yield Pfizer on safety (PFE's 85% payout ratio is concerning). The 62-year streak doubles Abbott's 52 years.

Abbott (ABT) is the closest competitor with 8.5% dividend growth vs. JNJ's 5.8%. But ABT's 1.8% starting yield means you wait years to match JNJ's current income. Better for younger investors prioritizing growth over yield.

Medtronic (MDT) offers higher yield (3.5%) but slower growth (4.5%). Medical device companies face more cyclicality than pharma. Good for income today, less for income growth.

Pfizer (PFE) yields 6.2% but the 85% payout ratio and post-COVID revenue challenges make this a value trap. The dividend may survive but don't expect meaningful growth.

AbbVie (ABBV) combines high yield (3.8%) with strong growth (8.2%), but Humira biosimilar pressure creates near-term uncertainty. More aggressive than JNJ, suitable for investors accepting higher risk.

Bottom line: If you can only own one healthcare dividend stock, JNJ is the unanimous choice. If you're building a diversified portfolio, pair JNJ's safety with ABT's growth and ABBV's yield.

40-Year DRIP Compounding Example

The true magic of JNJ isn't the 3.0% yield today—it's the compounding over decades. Let's run a real example showing what happens when you buy JNJ stock and reinvest dividends for 40 years.

This is why Dividend Kings like JNJ are retirement planners' favorites. You buy the stock in your 20s or 30s, reinvest dividends, and by retirement you're generating life-changing passive income.

The example above uses conservative 6% stock appreciation. JNJ's actual historical total return (dividends + price gains) is 9-10% annually. At 10% total return, that $10,000 grows to $452,000 in 40 years with $35,000+ in annual dividend income.

Want to run your own numbers? Use our DRIP calculator below to model JNJ with your specific investment amount, timeframe, and assumptions.

Pros and Cons: Is JNJ Right for You?

Who should buy JNJ? Conservative dividend investors prioritizing safety and reliability over maximum yield or growth. Retirees living on dividends. Young investors building a core portfolio position they'll hold forever.

Who should avoid JNJ? Aggressive investors seeking 6%+ yields or 10%+ dividend growth. Traders looking for quick gains. Anyone who panics over lawsuit headlines without understanding the financials.

Where to Buy Johnson & Johnson Stock

To buy JNJ shares commission-free with automatic dividend reinvestment (DRIP), you need a brokerage account. Here are the top-rated brokers for dividend investors in 2026.

All of these brokers offer zero commissions on stock trades, free dividend reinvestment plans, and fractional shares (so you can invest $100 instead of buying a full share at $161).

Frequently Asked Questions